The global sales of aquaculture immunostimulants is estimated to be worth USD 103.7 million in 2024 and anticipated to reach a value of USD 193.2 million by 2034. Sales are projected to rise at a CAGR of 6.4% over the forecast period between 2024 and 2034. The revenue generated by Aquaculture Immunostimulants in 2023 was USD 98.1 million.
As the market for aquaculture immunostimulants grows to fulfil the rising demand for seafood throughout the world, efficient disease control becomes more and more important. Immunostimulants provide a possible answer to this problem by providing the natural defenses of farmed fish and shellfish.
Currently, a lot of research and development is being done to provide novel and secure immunostimulants solutions specifically designed for the aquaculture industry.
The Aquaculture Immunostimulants Market has a great deal of potential to contribute significantly to the promotion of sustainable aquaculture methods, protecting aquatic species and reducing the ecological impact of the sector, as long as environmental concerns are present.
Global Aquaculture Immunostimulants Industry Assessment
Attributes | Key Insights |
---|---|
Historical Size, 2023 | USD 98.1 million |
Estimated Size, 2024 | USD 103.7 million |
Projected Size, 2034 | USD 193.2 million |
Value-based CAGR (2024 to 2034) | 6.4% |
The demand for natural and organic substitutes within the aquaculture immunostimulants market follows the prevailing trends in consumption, where consumers have evinced a greater interest in 'green' products. Triggered by growing awareness among consumers and producers regarding the impact of aquaculture on the environment, there has been a clear shift toward those solutions that cause minimal injury to the ecosystem.
These factors have ensured unprecedented demand for naturally derived immunostimulants, which are plant-based compounds, algae, and probiotics.
These natural immunostimulants support the health and robustness of farmed aquatic species and are also in line with the emphasis of the industry on sustainability and environmental consciousness.
With such natural immunostimulants, there would be less reliance on synthetic chemicals and antibiotics; hence, a more safe and eco-friendly way of carrying out aquaculture with respect to disease management would ensue, therefore fostering sustainability for the future of the industry.
Furthermore, aquaculture immunostimulants market involve a focused effort on farming shrimp and salmon. Both species continue to rank among the most valuable farmed species within the global aquaculture industry, which owes its positive performance to rising consumer demand for high-value seafood products.
However, shrimp and salmon farming are also singularly vulnerable to disease outbreaks, events that often lead to significant economic losses. This therefore calls for an increasing need for effective immunostimulants, improving immune systems and hence health and productivity in these species with time.
It will be necessary to bring targeted immunostimulants to the market that would be ready for application in both shrimp and salmon, if profitability and sustainability in these two key industrial sectors are to be achieved.
Immunostimulants enhance the natural defenses of such species, thus reducing mortality rates, improving growth performance, and increasing overall yield. The expected result is a steady supply of shrimp and salmon to meet world demand, adding strength to the long-term viability of the aquaculture industry as a whole.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The above table presents the expected CAGR for the global aquaculture immunostimulants market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.1%, followed by a slightly lower growth rate of 6.8% in the second half (H2) of the same decade.
Particular | Value CAGR |
---|---|
H1 | 7.1% (2023 to 2033) |
H2 | 6.8% (2023 to 2033) |
H1 | 6.4% (2024 to 2034) |
H2 | 5.9% (2024 to 2034) |
The above table presents the expected CAGR for the global aquaculture immunostimulants market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.1%, followed by a slightly lower growth rate of 6.8% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.4% in the first half and decrease moderately at 5.9% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Unleashing Growth: The Aquaculture Immunostimulants Market is growing amidst Rising Demand for Nutritious and Sustainable Seafood
Nutritious and sustainable dietary preferences by consumers have markedly influenced seafood demand, considered a healthy source of dietary protein and essential nutrients. With continued improvement in awareness of the health benefits of seafood, various species of fish and shellfish are continually consumed more and more.
This is also changing the eating tradition towards rising consumption of seafood, and this industry now has the task of meeting such demand.
Presently, there are more or less advanced methods of prevention and management of diseases that are increasingly being put to use by the aquaculture industry to maintain health status and productivity of farmed aquatic species. Amongst these, one of the most promising solutions includes the use of immunostimulants.
These work by strengthening fish and shellfish's innate immune systems against illnesses that would otherwise completely destroy aquaculture operations. Immunostimulants are essential for the long-term development and sustainability of aquaculture species because they increase disease resistance.
Besides this, immunostimulants represent an important contribution to recent efforts on environmental sustainability. Greater biological resistance reduces the application of antibiotics and other chemical therapies, most of which have devastating impacts on the environment and hence on the sustainability of aquaculture.
This means aquatic ecosystems remain healthy, consumer demand for responsible seafood is met, and it brings benefits to trade.
Growing Demand for Sustainable Seafood is Creating Opportunities for Aquaculture Immunostimulants Industry
This provides a very good avenue for growth in the global demand of aquaculture immunostimulants in markets that are focused on sustainable seafood farming to improve the health and productivity of farmers' aquatic stock and those of aquaculture operators.
Secondly, the farmers and aquaculture operators often adjust priorities between health and productivity while demanding environmental settings and other efficiency improvements in the farms. The changing dimensions are providing a gateway toward the use of immunostimulants, which are indispensable for enhancing the immune systems in fish and shellfish to provide resilience against diseases.
Aquaculture practices in tune with growing ecological awareness are slowly changing toward ecological aquaculture, wherein the practice of aquaculture ensures minimum ecological damage. Organic aquaculture is one where there is a minimum use of chemicals, natural inputs, and lesser quantitative use.
Composite fish culture is done whereby optimization from different species is taken into one system. Integrated aquaculture is combined with any other aquaculture with fish farming. These could be initiated further to add value on product diversification for optimal resource utilization. Closed recirculation systems can be minimally used for water and effluent.
These innovative practices are concurrent with environmental sustainability objectives and further raise the demand for effective solutions in support of health and productivity among farmed species. The use of immunostimulants alone can result in more robust aquaculture systems because of the healthier aquatic environment brought about by the reduced application of antibiotics and/or other chemical treatments.
In fact, for this-also-the market of immunostimulants in aquaculture is expressing great new potentials, enhancing the tendencies toward sustainability with those toward optimum fish health.
High Development and Production Costs Limit Adoption and Market Growth of Aquaculture Immunostimulants Industry
One of the most significant constraints to the Aquaculture Immunostimulants Market is the total overall cost of the development and production of these products. The requirement to develop a successful immunostimulants necessitates a financial commitment to research and development (R&D) and also to a rigorous set of experimental trials for safety and efficacy purposes.
There is also considerable complexity in developing a new immunostimulants, as well as a need for advanced technology, that continues to escalate overall cost. The overall cost factor creates a significant financial hurdle for manufacturers that cannot increase prices to remain competitive.
When there are significant costs associated with production in aquaculture, this causes inflated costs downstream to the end-users which are primarily farmers and businesses with limited resources. Immunostimulants and similar products are expensive and sometimes represent hurdles for farmer and aquaculture businesses.
Consequently, many smaller to medium-sized enterprises may be less willing or less able to use these products, which will lead to a lower penetration of the market.
Cost is subsequently a barrier to the widespread availability and affordability of immunostimulants and this has a direct relationship on the usages of immunostimulants in the aquaculture space. The lower adoption rates of aquaculture businesses is not only a key driver of the lagging advancement of market growth, but is a vital infusionary cap.
Large-scale aquaculture operations may have the ability to be an advocate for potentially efficient and progressive products, this needs to lead some evidence of adoption from small to medium sized operations alongside popularization of efficiency and sustainability of products.
There are feasible avenues of overcoming cost barriers depending on technological advancement, economies of scale to facilitate cost-advancement, and/or financial programs/incentives to advance utilization of immunostimulants products.
The global aquaculture immunostimulants industry recorded a CAGR of 4.3% during the historical period between 2019 and 2023. The growth of aquaculture immunostimulants industry was positive as it reached a value of USD 98.1 million in 2023 from USD 79.4 million in 2019.
The aquaculture immunostimulants industry has seen remarkable development since its beginnings. Primarily, the initial aim was to use traditional methods of control, like antibiotics, whereas immunostimulants represented a newer concept for use. Investigation into these products began in the late 1990s and developed in the 2000s, mainly to address disease incidence and improve the health of farmed aquatic animals.
During this stage, simple immunostimulants including probiotics and nucleotides were presented. Although these initial developments allowed for the enhanced understanding of aquatic immunity, overall growth of this class of product was slow to market because of the high costs, low awareness and impact of divisive regulations experienced at the time.
The growing global demands for sustainable and nutritious seafood has grown aquaculture dramatically and established new markets for effective methods to manage disease. The rise in demand for seafood has led to growth in the market for immunostimulants, as one of the most important uses is as an enhancement to immunity as a means of disease resistance and improving long-term health of farm-raised aquatic animals.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 65.2% in global market. These market leaders are characterized by high production capacity and a wide product portfolio.
These market leaders are distinguished by their extensive expertise in manufacturing and reconditioning across multiple packaging formats and a broad geographical reach, underpinned by a robust consumer base. They provide a wide range of series including reconditioning, recycling, and manufacturing utilizing the latest technology and meeting the regulatory standards providing the highest quality.
Prominent companies within tier 1 include DSM Nutritional Products, Alltech, Kemin Industries, Inc, BioMar Group, and Evonik Industries among others.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 33.7% market share. These are characterized by a strong presence overseas and strong market knowledge.
These market players have good technology and ensure regulatory compliance but may not have advanced technology and wide global reach. Prominent companies in tier 2 include Adisseo, Norel S.A, INVE Aquaculture, esaffre (Phileo) among others.
Finally, Tier 3 companies, such as Lallemand Inc., ADM among others are essential for the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the aquaculture immunostimulants market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a value share of 82.3% through 2034. In Asia Pacific, South Korea is projected to witness a CAGR of 7.4% by 2034.
Countries | Value CAGR (2024 to 2034) |
---|---|
Canada | 7.3% |
Brazil | 5.2% |
France | 8.9% |
Russia | 6.4% |
Japan | 5.5% |
South Korea | 7.4% |
Spain | 6.3% |
USA Aquaculture Immunostimulants market is poised to exhibit a CAGR of 6.8% between 2024 and 2034. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
The growing demand for seafood in the USA keeps boosting the immunostimulants market for aquaculture. In the main, immunostimulants help aquaculture producers improve the immune systems of farmed fish and shellfish and get healthier yields with minimal use of antibiotics. All these changes have come along due to consumer preferences, presently oriented toward sustainable and healthy options of seafood.
According to the National Oceanic and Atmospheric Administration Fisheries, in an article released in September 2023, between 70% and 85% of seafood consumed in the USA is imported, with over half coming from foreign aquaculture.
This, therefore, is a situation that has outlined the increasing importance of aquaculture practices in home waters, the role of immunostimulants in improving production efficiency and sustainability, meeting market demand, and improving trade challenges.
East Asia, spearheaded by China currently holds around 48.3% share of the East Asia aquaculture immunostimulants industry. East Asia’s market is anticipated to grow at a CAGR of 8.9% throughout the forecast period.
The rapid growth in China's aquaponics industry also means demand for aquaculture immunostimulants will rapidly rise. In the growing sector, aquaculture immunostimulants become indispensable to boost fish and shellfish health and productivity in these aquaponics systems. The improved resistance to diseases and lower use of antibiotics mean that immunostimulants support a solution to the high-quality, sustainable aquaculture challenge.
It is further mired by the growing seafood market in China, which aims to meet the increasing consumer's preference for healthy and eco-friendly seafood. Emphasis on sustainability in aquaculture and the dire need for appropriate immunostimulants are the reasons why these are the imperative needs that will help the growth of the industry with long-term health and productivity in the aquaponics systems.
UK is expected to have a strong foothold when it comes to technology innovation. In 2023 the country is projected to account for almost 11.9% of the European aquaculture immunostimulants market.
A marked shift in emphasis toward combating disease outbreaks in aquaculture with the use of immunostimulants is occurring in the UK. Increasing awareness of and necessity for sustainability within aquaculture, along with a structured move away from antibiotics, are driving the heightened focus on the application of immunostimulants.
Increased concerns over antibiotic resistance and environmental responsibilities in the UK has led to requests from within the aquaculture sector for alternative means of enhancing disease resistance without major changes to the ecosystem.
Immunostimulants support this paradigm shift in aquaculture within the UK and further afield by enhancing the immune systems of both farmed fish and shellfish leading to lower regularity and severity of disease outbreaks.
Improvements to the immune system can reduce losses brought on by disease and create a more robust aquaculture environment. Enhancing natural resistance with immunostimulants reduces reliance on chemical treatments and promotes the wellbeing of aquatic life.
A growing requirement in the UK market will develop for the using immunostimulants for healthy fish and shellfish while developing a reduction to antibiotics and improving practices of sustainability. The shift in aquaculture practice also indicates a shift in recognition of better ways of advancing aquaculture in a more sustainable manner as well as uncertainty with the pacing of the industry.
The section contains information about the leading segments in the industry. By Immunostimulants type, the Glucans segment is estimated to grow at a CAGR of 5.9% throughout 2034.
Immunostimulants type | Glucans |
---|---|
Value Share (2024) | 36.8% |
In 2024, the Glucans segment emerges as the revenue leader, commanding nearly 37.0% of the market share. Due to their exceptional capacity to boost immune response in aquatic species, the Glucans sector has emerged as a global leader in the aquaculture immunomodulatory sector.
Glucans are strong polysaccharides from a range of natural sources including yeast and fungi that possess important immune-modulating characteristics and work by improving immune function through immune stimulation and can enhance overall resistance of an aquatic organism to pathogens.
The significant market demand for Glucans demonstrates that there is a notable emphasis on improving fish and shellfish health and manufacturing in aquaculture. Glucans improve immune function, thereby supporting the prevention of disease outbreaks and promoting the reduction of antibiotic reliance in aquaculture, but they also improve health and welfare in aquatic species.
This is becoming more relevant in the aquaculture landscape as there are increasing requests for production methods that are more sustainable, or environmentally conscious.
End User | Fish Farming Companies |
---|---|
Value Share (2024) | 54.8% |
The fish farming companies segment will account for a revenue of over USD 53.7 million in the aquaculture immunostimulants market by 2024 end. It is also poised to expand at a CAGR of 4.5% across the forecast period.
Fish farming firms are the primary end users in the aquaculture immunostimulants market for a couple various reasons. First, they face the ongoing battle of managing and preventing diseases in their farmed fish and its effect on productivity and profitability cannot be understated.
Immunostimulants, are fundamental for inducing the immune systems of aquatic species, lowering the risk of outside disease outbreaks, and ultimately reducing anti-microbial and other chemical additives. Not only does this benefit the health of fish, but it also leads to the rising trend of sustainable aquaculture.
Furthermore, fish farming firms are at the forefront of applying technologies and new management techniques to maximize efficiency and productivity. Immunostimulants continue to allow for optimal fish performance in growth, feeding conversions, and general condition, subsequently increasing yield for seafood products.
Substantial investments in the aquaculture immunostimulants industry are increasingly directed towards research and development (R&D) to drive innovation and enhance product offerings. Companies are committing significant resources to develop advanced immunostimulants solutions that improve disease resistance, boost the health of farmed fish and shellfish, and support sustainable aquaculture practices.
Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Aquaculture Immunostimulants Market
In terms of material, the industry is divided into Glucans, Muramyldipeptides, Chitin & Chitosan, and Yeast Derivatives among other Immunostimulants.
In terms of species, the industry is segregated into Salmonids, Marine fish, Freshwater fish, Shellfish, Shrimp, and Farm fish among others.
The industry is classified by end user as Fish Farming Companies, Fish Veterinary Clinics and Aquatic Research and Development Institutions.
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.
The global aquaculture immunostimulants industry is projected to witness CAGR of 6.4% between 2024 and 2034.
The global aquaculture immunostimulants industry stood at USD 98.1 million in 2023.
The global aquaculture immunostimulants industry is anticipated to reach USD 193.2 million by 2034 end.
China is set to record the highest CAGR of 11.7% in the assessment period.
The key players operating in the global aquaculture immunostimulants industry include DSM Nutritional Products, Alltech, Nutriad International NV, Kemin Industries, Inc, BioMar Group, Evonik Industries, Adisseo, Nutreco N.V. (Skretting), Novus International Inc., Norel S.A, INVE Aquaculture, Lesaffre (Phileo), Lallemand Inc., ADM.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Value Added Insights, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Immunostimulants Type 5.2. By Species 5.3. By End User 5.4. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Immunostimulants Type 6.1. Glucans 6.2. Muramyldipeptides 6.3. Chitin & Chitosan 6.4. Yeast Derivatives 6.5. Other Immunostimulants 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Species 7.1. Salmonids 7.2. Marine fish 7.3. Freshwater fish 7.4. Shellfish 7.5. Shrimp 7.6. Farm fish 7.7. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 8.1. Fish Farming Companies 8.2. Fish Veterinary Clinics 8.3. Aquatic Research and Development Institutions 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. East Asia 9.4. South Asia and Pacific 9.5. Western Europe 9.6. Eastern Europe 9.7. Middle East and Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Immunostimulants Type, Species, and End User for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. DSM Nutritional Products 19.2. Alltech 19.3. Nutriad International NV 19.4. Kemin Industries, Inc 19.5. BioMar Group 19.6. Evonik Industries 19.7. Adisseo 19.8. Nutreco N.V. (Skretting) 19.9. Novus International Inc. 19.10. Norel S.A 19.11. INVE Aquaculture 19.12. Lesaffre (Phileo) 19.13. Lallemand Inc. 19.14. ADM
Explore Healthcare Insights
View Reports